 Anti-HIV Agents
"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1998 | 4 | 4 | 8 | | 1999 | 4 | 3 | 7 | | 2000 | 4 | 1 | 5 | | 2001 | 5 | 1 | 6 | | 2002 | 4 | 1 | 5 | | 2003 | 2 | 2 | 4 | | 2004 | 9 | 1 | 10 | | 2005 | 8 | 4 | 12 | | 2006 | 5 | 3 | 8 | | 2007 | 5 | 2 | 7 | | 2008 | 9 | 2 | 11 | | 2009 | 10 | 3 | 13 | | 2010 | 10 | 2 | 12 | | 2011 | 8 | 8 | 16 | | 2012 | 17 | 2 | 19 | | 2013 | 14 | 4 | 18 | | 2014 | 23 | 6 | 29 | | 2015 | 15 | 6 | 21 | | 2016 | 33 | 9 | 42 | | 2017 | 30 | 7 | 37 | | 2018 | 28 | 6 | 34 | | 2019 | 25 | 6 | 31 | | 2020 | 31 | 6 | 37 | | 2021 | 42 | 5 | 47 | | 2022 | 41 | 0 | 41 | | 2023 | 33 | 2 | 35 | | 2024 | 21 | 9 | 30 | | 2025 | 37 | 4 | 41 | | 2026 | 27 | 3 | 30 |
To return to the timeline, click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Landovitz RJ, Fogel JM, Gao F, Hanscom B, Piwowar-Manning E, Moser A, Marzinke MA, Cyktor J, Seisa M, Halvas EK, Kofron R, Jennings A, Clement M, Tran HV, Gaur A, Fichtenbaum CJ, Asmelash A, Soto-Torres L, Rooney JF, Rinehart AR, Cohen MS, Grinsztejn B, Eshleman SH. Prospective HIV RNA Screening With Long-acting Cabotegravir Pre-exposure Prophylaxis in HPTN 083. Clin Infect Dis. 2026 Oct 28; 83(4):e787-e794.
-
Hazra A, Chan PA, Clement M, Kaperak CJ, Safa H, Havens JP, Springer SA, Blumenthal J, Spinelli M, Doblecki-Lewis S, Multani A, Gipson J, Cherabie J, Vail R, Sukumaran S, Cannon CA, Lillis R, Butler I, Turner C, Taraschi E, Narcisse-Cempini G, Kunzmann L, Smith R, Halbur D, Patel RR. Real-World Implementation Outcomes of Lenacapavir for HIV Preexposure Prophylaxis: Early Findings From a Multicenter United States Cohort. Clin Infect Dis. 2026 Oct 28; 83(4):596-600.
-
Rogg L, Nuñez SA, Mingrone MV, Domingo P, Rolle CP, Güerri-Fernandez R, Estrada V, Lopez M, Hanan N, Ghita GL, Jeffrey JL, Underwood M, Castillo-Mancilla JR, Halliday F, Ezeadi E, Gartland M. Proof-of-Concept Phase 2a Trial of VH4524184: An Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile. Clin Infect Dis. 2026 Oct 28; 83(4):e819-e825.
-
Irie WC, Corneli A, Perry B, Kelsey C, Bickham J, Davenport T, Naresh A, Holman S, Clement M. Start the Conversation: Development of a Training Program to Build OB/GYN Resident Capacity for PrEP Prescribing in Routine Care. J Int Assoc Provid AIDS Care. 2026 Jan-Dec; 25:23259582261488339.
-
Yu Y, Brooks KM, Doncel GF, Best BM, Marzinke MA, Mirochnick M, Anderson PL, Myer L, Celum C, Heffron R, Coleman J, Davey DLJ, Zhang L, von Kleist M, Hendrix CW, Momper JD, Bies R, Scott RK. Predicting Oral HIV Pre-Exposure Prophylaxis Efficacy in Cisgender Women Across Pregnancy and Postpartum. J Clin Pharmacol. 2026 Sep; 66(9):e70278.
-
Tagliaferri Rael C, Das D, Giguere R, Porter J, Bryndza Tfaily E, Tuswa Haynes C, Ho T, McKenna S, Lopez-Ríos J, Lentz C, Dolezal C, Stonbraker S, Hendrix C, D'Aquila RT, Hope TJ. Provider Preferences on Existing and Potential Future Biomedical HIV Prevention Products: A Qualitative Study in the United States, Thailand, and South Africa. AIDS Res Hum Retroviruses. 2026 Oct-Nov; 42(10-11):307-317.
-
Haw NJL, Hogan B, Humes E, Coburn SB, Zheng C, Cheng Y, Zhang Y, Gebo KA, Lam JO, Karris MY, Zalla LC, Horberg MA, Napravnik S, Gill MJ, Althoff KN, Lesko CR. New to cohort, not new to care: leveraging historical data in HIV clinical cohorts in the United States. Am J Epidemiol. 2026 08 05; 195(8):2287-2296.
-
Dunbar A, Rakhmanina N, Unternaher J, Anderson PL, Brooks KM. Long-Acting Injectable Antiretroviral Therapies for HIV Treatment and Prevention: Clinical Pharmacology, Recent Advances and Future Opportunities. J Clin Pharmacol. 2026 Aug; 66(8):e70249.
-
Koethe JR, Lake JE, Kantor A, Smeaton L, Erlandson K, Moran L, Belaunzaran-Zamudio P, Landay A, Campo RE, Debroy P, Bennet JA, O'Halloran J, Han WM, Alli O, Leonard M, Gulick RM. A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391). Clin Infect Dis. 2026 07 23; 83(1):e81-e89.
-
Puccinelli M, Mayer KH, Esquivel-Mendoza JA, Porras A, Psaros C, Krakower D, Doblecki-Lewis S, Anderson PL, Mimiaga MJ, Safren SA. Life-steps for PrEP nurse-delivered adherence intervention: Protocol for a multisite randomized clinical trial. Contemp Clin Trials. 2026 Sep; 168:108405.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|